1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > REVA Medical, Inc. (RVA) - Product Pipeline Analysis, 2015 Update

Summary

REVA Medical, Inc. (REVA) is a medical device company that develops minimally invasive medical devices. The company’s product includes bioresorbable polymers. Its product bioresorbable polymers can be applied to a variety of medical applications. REVA’s fantom sirolimus-eluting bioresorbable scaffold is designed to provide acute benefits as permanent drug-eluting metal stents. The company also develops proprietary polymers for scaffold performance. Its polymer also serves as the drug-delivery coating on fantom. The company has a first-generation scaffold in clinical evaluation which was held trial in Australia, Brazil, Europe and New Zealand. REVA is headquartered in San Diego, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company REVA Medical, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

REVA Medical, Inc. (RVA) - Product Pipeline Analysis, 2015 Update
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
REVA Medical, Inc. Company Snapshot 5
REVA Medical, Inc. Company Overview 5
Key Information 5
REVA Medical, Inc. Pipeline Products and Clinical Trials Overview 6
REVA Medical, Inc. - Pipeline Analysis Overview 8
Key Facts 8
REVA Medical, Inc. - Major Products and Services 9
REVA Medical, Inc. Pipeline Products by Development Stage 10
REVA Medical, Inc. Clinical Trials by Trial Status 11
REVA Medical, Inc. Pipeline Products Overview 13
Fantom Sirolimus-Eluting Bioresorbable Scaffold 13
Fantom Sirolimus-Eluting Bioresorbable Scaffold Product Overview 13
Fantom Sirolimus-Eluting Bioresorbable Scaffold Clinical Trial 14
ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold 15
ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold Product Overview 15
ReZolve2 16
ReZolve2 Product Overview 16
REVA Medical, Inc. - Key Competitors 17
REVA Medical, Inc. - Key Employees 18
REVA Medical, Inc. - Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
REVA Medical, Inc., Recent Developments 20
Aug 20, 2015: REVA Appoints Regina Groves as Chief Executive Officer 20
May 21, 2015: REVA Releases Initial Clinical Results for Fantom Scaffold 20
May 18, 2015: REVA to Present at EuroPCR 2015 21
May 14, 2015: REVA Expands FANTOM II Clinical Trial to Australia 21
May 13, 2015: REVA Undertakes Search for Chief Executive Officer 21
Apr 22, 2015: REVA Expands FANTOM II Clinical Trial to Europe 21
Mar 25, 2015: REVA Appoints Scott Huennekens to Board of Directors 22
Mar 15, 2015: REVA Initiates FANTOM II Clinical Trial 22
Feb 23, 2015: REVA Bioresorbable Program Update at CRT Conference 23
Jan 28, 2015: REVA Appoints Dr. Ross Breckenridge to Board of Directors 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
REVA Medical, Inc., Key Facts 5
REVA Medical, Inc. Pipeline Products and Clinical Trials Overview 6
REVA Medical, Inc. Pipeline Products by Equipment Type 6
REVA Medical, Inc. Pipeline Products by Indication 7
REVA Medical, Inc. Clinical Trials by Trial Status 7
REVA Medical, Inc., Key Facts 8
REVA Medical, Inc., Major Products and Services 9
REVA Medical, Inc. Number of Pipeline Products by Development Stage 10
REVA Medical, Inc. Pipeline Products Summary by Development Stage 10
REVA Medical, Inc. Clinical Trials by Trial Status 11
REVA Medical, Inc. Clinical Trials Summary 12
Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Status 13
Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Description 13
Fantom Sirolimus-Eluting Bioresorbable Scaffold - FANTOM I Clinical Trial 14
Fantom Sirolimus-Eluting Bioresorbable Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold 14
ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status 15
ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description 15
ReZolve2 - Product Status 16
ReZolve2 - Product Description 16
REVA Medical, Inc., Key Employees 18

List of Figures
REVA Medical, Inc. Pipeline Products by Equipment Type 7
REVA Medical, Inc. Pipeline Products by Development Stage 10
REVA Medical, Inc. Clinical Trials by Trial Status 11

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.